Objective To investigate the efficacy of different doses of ateplase in the treatment of acute ischemic stroke(AIS)patients with admitted hyperglycemia and its impact on the prognosis.Methods A total of 186 AIS patients with admitted hyperglycemia who underwent intravenous thrombolysis with ateplase in Xianyang Hospital,Yan'an University from January 2020 to December 2022 were selected.They were randomly divided into the standard dose group(93 cases)and the low dose group(93 cases)by the random number table method.Both groups were treated with insulin to lower blood sugar levels.The standard dose group had a dose of 0.9 mg/kg of alteplase,with a maximum dose of 90 mg.The low dose group had a dose of 0.6 mg/kg of alteplase,with a maximum dose of 60 mg.The short-term efficacy,90-day prognosis,mortality rate and incidence of bleeding events between the two groups were compared.Results There were no statistically significant differences in the total effective rate after 24 hours of treatment and short-term good prognosis rate after 7 days of treatment between the two groups(P＞0.05).There was no statistically significant difference in the long-term prognosis between the two groups(P＞0.05).The mortality rate of the low dose group was lower than that of the standard dose group(P＜0.05).The incidence of bleeding events of the low dose group was lower than that of the standard dose group(P＜0.05).Conclusion Compared with the standard dose,low dose ateplase therapy for AIS with admission hyperglycemia can reduce the incidence of bleeding events and mortality in patients,which can benefit them.
维普
万方数据